Among them, based on the trial results of IMpower010, the US FDA finally approved adjuvant atelizumab after surgical treatment and platinum-based chemotherapy for patients with PD-L1 expression ≥ 1% in stage II-IIIA NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.